國際產業動態
川普政府公布2018年預算文件 FDA的產品審查費用未來將增加一倍以上
2017-03-17

資料來源:https://www.reuters.com/article/usa-trump-budget-health-idUSL2N1GT21E

The cost to healthcare companies for U.S. regulatory review of their products, including drugs and medical devices, would more than double under the Trump administration's proposed 2018 budget.

For 2018, the Trump administration has budgeted over $2 billion in fees to be collected by the U.S. Food and Drug Administration from industry, twice as much as in 2017, according to budget documents released on Thursday.

Citing a constrained budget environment, the proposed budget said industries that benefit from the FDA's approval "can and should pay for their share."

In return, the budget said it also offered measures that would help speed up the approval process for new drugs and other products.

The FDA has been criticized by lawmakers for not being quick enough at approving drugs, and President Donald Trump told Congress earlier this year that he aimed to speed up the approval of drugs.

The FDA has been charging companies to review their products since 1992. Most of the user fees collected are for prescription drugs - around $866 million estimated in 2017 - and generic drugs - around $324 million, according to the FDA website. The FDA's 2017 budget was $5.1 billion, the website said.

The budget does not say if the fee increases would be evenly spread or directed in a particular area.

The budget did not provide specifics on what measures to speed up approvals might include.

 

本網站中所有資料(包括圖檔及文字檔),著作權皆屬本會所有(除另有註明者,或本會網站連結至外部之網站除外),如有引用,請確實註明出處來源。<完整資訊>
© 2024 Institute for Biotechnology and Medicine Industry (IBMI) All rights reserved.
地址:115 台北市南港區忠孝東路七段508號9樓 電話:(02)2655-8168 傳真:(02)2655-7978